Avoiding Anticoagulation After IntraCerebral Haemorrhage

Randomised controlled trials (RCTs) demonstrate a substantial benefit from oral anticoagulant drugs for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation (AF). However, these RCTs excluded patients with prior intracerebral haemorrhage (ICH). Therefore, guidelines are unable to recommend whether oral anticoagulant drugs, in particular non-vitamin K antagonist (called direct OAC) - can be used for patients with AF after an intracerebral haemorrhage. Roughly 30% of adults with ICH have AF but in 2017 it remains unclear whether they should start oral anticoagulant drugs, be treated with left atrial appendage closure (LAAC) or avoid anticoagulation and LAAC.

NCT Number	NCT03243175
Lead Sponsor	University Hospital, Lille Collaborators: Ministry of Health, France, Institut National de la Santé Et de la Recherche Médicale, France
Conditions	Intracerebral Hemorrhage, Atrial Fibrillation, Microhaemorrhage
Enrollment	300 participants
Start Date	2019-01-17
Primary Completion	2029-01 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2026-04-07